Search clinical trials for: MK-1092, 64 nmol/kg

Total 86 results

Merck Sharp & Dohme LLC

Completed

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Bracco Diagnostics, Inc

Completed

Crossover Comparison of MultiHance and Dotarem (BENEFIT)

Brain Disease

United States
Imperial College London

Completed

The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment

Infertility

United Kingdom
Guerbet

Completed

Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis

Chronic Liver Disease | HepatoCellular Carcinoma

France
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Bayer

Completed

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Brain Diseases | Spinal Cord Diseases

United States, Colombia, Argentina, Brazil
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Bayer

Completed

A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants

Healthy Volunteers | Contrast Enhancement in Magnetic Resonance Imaging

China
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy (RECIR)

Prostate Cancer | Neuromuscular Blockade

Italy
University Hospital, Grenoble

Not yet recruiting

Acceleration of the Kinetics of Diffusion of Gadolinium in the Perilymphatic Structures of the Inner Ear. (FAST-HYDROPS)

Inner Ear ; Meniere's Disease; Imaging
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

United States, Australia, Brazil, Italy, United Kingdom
ArQule, Inc. (a wholly owned subsidiary of Merck...
Worldwide Clinical Trials

Terminated

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) (MOSAIC)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

United States, Australia, Italy, Spain
University of Aarhus
University of Copenhagen

Recruiting

Protein and Magnesium in Ulcerative Colitis (PAMUC)

Inflammatory Bowel Diseases | Colitis, Ulcerative | Magnesium Deficiency | Nutritional Deficiency | Protein Deficiency

Denmark
Egetis Therapeutics
Solasia Pharma K.K.

Terminated

Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer (POLAR-A)

Colorectal Cancer | Chemotherapy-induced Peripheral Neuropathy

France, Korea, Republic of, Italy, Japan, Spain, Belgium, Germany, United Kingdom, Czechia, Taiwan
Egetis Therapeutics
Pharma Consulting Group AB

Completed

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer (PLIANT)

Advanced Metastatic (Stage IV) Colorectal Cancer

Sweden, United States, Bulgaria, Denmark, Georgia, Germany, Portugal, Serbia
Chiesi Farmaceutici S.p.A.
ICON plc

Recruiting

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease (RISE)

Fabry Disease

Japan
Universitaire Ziekenhuizen KU Leuven

Completed

Effect of Pancreatic Polypeptide on Gastric Motor Function and Food Intake in Humans

Hunger

Belgium
Zealand University Hospital
University of Copenhagen; Glostrup University Hospital, Copenhagen

Unknown

GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow

Healthy

Denmark
Alexion Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency | Cholesterol Ester Storage Disease(CESD) | LAL-Deficiency

France, United States, United Kingdom, Czechia
Guerbet

Completed

Cardiac Safety Evaluation of P03277

Healthy Volunteers

Belgium
MediBeacon

Completed

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

Acute Kidney Injury

United States
Amgen

Completed

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma
Amgen

Completed

A Phase II Study to Treat Advanced Malignant Glioma

Advanced Malignant Glioma
Clinical Hospital Centre Zagreb
Merck Sharp & Dohme LLC

Completed

Natriuretic Effect of GLP-1in Healthy Non Obese Subjects

Sodium Excretion by Urination

Croatia
Egetis Therapeutics
Solasia Pharma K.K.

Terminated

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) (POLAR-M)

Colorectal Cancer | Chemotherapy-induced Peripheral Neuropathy

France, Korea, Republic of, United States, Italy, United Kingdom, Hong Kong, Spain, Hungary, Belgium, Japan, Germany, Czechia, Taiwan
Chiesi Farmaceutici S.p.A.
ICON plc

Not yet recruiting

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease (FLY)

Fabry Disease
Merck Sharp & Dohme LLC

Completed

Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)

Anesthesia
Petrovsky National Research Centre of Surgery

Recruiting

Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients

Thoracic Aortic Aneurysm | Thoracic Aortic Dissection | Cardiac Valve Disease | Aortic Aneurysm and Dissection

Russian Federation
Merck Sharp & Dohme LLC

Completed

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Hyperlipidemia | Hypercholesteremia
Medical University of Vienna
Polymun Scientific, Vienna, Austria

Completed

Recombinant Human Superoxide Dismutase (rhSOD) and Vascular Reactivity

Inflammation

Austria
Guerbet

Completed

Safety and Dialysability of Dotarem® in Dialysed Patients

End-stage Renal Failure

Belgium
Morphotek

Completed

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Adenocarcinoma of the Lung

Spain, United States, Australia, Canada, Germany, Italy, Poland, Russian Federation
Merck Sharp & Dohme LLC

Completed

Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

Colorectal Cancer
MacroGenics
Merck Sharp & Dohme LLC

Completed

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Stomach Cancer | Gastric Cancer | Esophageal Cancer

Korea, Republic of, United States, Taiwan, Singapore, Canada
Regeneron Pharmaceuticals

Recruiting

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Melanoma

United States, Australia, Spain, United Kingdom, Canada, Brazil, Mexico, Germany, Ireland, South Africa, France, Israel, Georgia, Turkey, Italy, Poland, Chile, Argentina, Belgium, Czechia, Romania, Greece
Jason R. Brown
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Active, not recruiting

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Bladder Cancer | Urothelial Carcinoma

United States
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)

Fungal Infections
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

Metastatic Colorectal Cancer

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

Urothelial Carcinoma Associated 1 RNA, Human
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
The Second Affiliated Hospital of Shandong First...

Not yet recruiting

The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

Neuromuscular Blockade

United States, Austria, Belgium, Denmark, Germany
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966)

Biliary Tract Carcinoma

United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Spain, Taiwan, Thailand, Turkey, United Kingdom
Arno Therapeutics

Unknown

Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

Glioblastoma Multiforme | Gliosarcoma | GBM

United States, Canada
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Colorectal Cancer

United States, Australia, Canada, Chile, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Malaysia, Norway, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Colorectal Cancer

China
LENZ Therapeutics, Inc

Completed

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Presbyopia

United States
Merck Sharp & Dohme LLC

Completed

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

Reversal of Neuromuscular Blockade

United States, Austria, Denmark, Germany
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

Colorectal Neoplasms

United States, Argentina, Australia, Canada, China, Denmark, Germany, Israel, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom

Search clinical trials for: MK-1092, 64 nmol/kg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations